IS2003B - Kamptóþesín afleiður sem verka gegn æxlum - Google Patents

Kamptóþesín afleiður sem verka gegn æxlum

Info

Publication number
IS2003B
IS2003B IS6031A IS6031A IS2003B IS 2003 B IS2003 B IS 2003B IS 6031 A IS6031 A IS 6031A IS 6031 A IS6031 A IS 6031A IS 2003 B IS2003 B IS 2003B
Authority
IS
Iceland
Prior art keywords
act against
against tumors
camptothecin derivatives
camptothecin
derivatives
Prior art date
Application number
IS6031A
Other languages
English (en)
Other versions
IS6031A (is
Inventor
Penco Sergio
Merlini Lucio
Zunino Franco
Carminati Paolo
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Istituto Nazionale Per Lo Studio E La Cura Dei Tumori filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of IS6031A publication Critical patent/IS6031A/is
Publication of IS2003B publication Critical patent/IS2003B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6031A 1999-03-09 2001-07-31 Kamptóþesín afleiður sem verka gegn æxlum IS2003B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity
PCT/EP2000/001570 WO2000053607A1 (en) 1999-03-09 2000-03-08 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
IS6031A IS6031A (is) 2001-07-31
IS2003B true IS2003B (is) 2005-04-15

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6031A IS2003B (is) 1999-03-09 2001-07-31 Kamptóþesín afleiður sem verka gegn æxlum

Country Status (38)

Country Link
US (2) US6242457B1 (is)
EP (1) EP1044977B1 (is)
JP (1) JP4610743B2 (is)
KR (1) KR100702085B1 (is)
CN (1) CN1139592C (is)
AR (1) AR022860A1 (is)
AT (1) ATE216998T1 (is)
AU (1) AU774174B2 (is)
BG (1) BG65032B1 (is)
BR (1) BR0008840B1 (is)
CA (1) CA2362760C (is)
CO (1) CO5180590A1 (is)
CZ (1) CZ304465B6 (is)
DE (1) DE69901379T2 (is)
DK (1) DK1044977T3 (is)
EA (1) EA003605B1 (is)
EE (1) EE04679B1 (is)
EG (1) EG23999A (is)
ES (1) ES2175919T3 (is)
HR (1) HRP20010667B1 (is)
HU (1) HU229506B1 (is)
IL (2) IL144958A0 (is)
IS (1) IS2003B (is)
ME (2) MEP4008A (is)
MX (1) MXPA01009081A (is)
NO (1) NO328363B1 (is)
NZ (1) NZ513393A (is)
PE (1) PE20001485A1 (is)
PL (1) PL222208B1 (is)
PT (1) PT1044977E (is)
RS (1) RS50405B (is)
SI (1) SI1044977T1 (is)
SK (1) SK287561B6 (is)
TN (1) TNSN00045A1 (is)
TR (1) TR200102603T2 (is)
TW (1) TWI272272B (is)
WO (1) WO2000053607A1 (is)
ZA (1) ZA200107408B (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
US7105492B2 (en) 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
CA2559532A1 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
AU2005244768B2 (en) 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
JP5345323B2 (ja) * 2004-12-15 2013-11-20 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 癌を処置するための治療剤の組合せ
US7799921B2 (en) 2004-12-21 2010-09-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Stereoselective process and crystalline forms of a camptothecin
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
AU2006270297B2 (en) 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN101287474B (zh) * 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
WO2007017513A2 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
MY149606A (en) * 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
RS52272B (sr) * 2005-12-21 2012-10-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Lečenje tumora otpornih na lek
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
JP5765937B2 (ja) * 2007-08-01 2015-08-19 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 小児腫瘍の治療
EP2096113A1 (en) * 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2025252101A1 (zh) * 2024-06-05 2025-12-11 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
NZ245112A (en) * 1991-11-15 1995-07-26 Smithkline Beecham Corp Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
DE69728152T2 (de) * 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate

Also Published As

Publication number Publication date
KR100702085B1 (ko) 2007-04-02
AR022860A1 (es) 2002-09-04
KR20010102519A (ko) 2001-11-15
CZ304465B6 (cs) 2014-05-21
AU3160400A (en) 2000-09-28
CA2362760C (en) 2009-08-18
NZ513393A (en) 2003-04-29
IS6031A (is) 2001-07-31
CN1139592C (zh) 2004-02-25
NO20014128L (no) 2001-08-24
CZ20013077A3 (cs) 2002-01-16
IL144958A0 (en) 2002-06-30
CO5180590A1 (es) 2002-07-30
YU64301A (sh) 2005-07-19
JP2002539128A (ja) 2002-11-19
ZA200107408B (en) 2002-05-29
BG105810A (en) 2002-06-28
ES2175919T3 (es) 2002-11-16
DE69901379T2 (de) 2002-11-07
MXPA01009081A (es) 2002-08-30
HRP20010667A2 (en) 2002-08-31
MEP4008A (xx) 2010-02-10
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
TR200102603T2 (tr) 2002-01-21
US6242457B1 (en) 2001-06-05
BR0008840A (pt) 2002-01-08
EE200100466A (et) 2002-12-16
PL222208B1 (pl) 2016-07-29
EP1044977A1 (en) 2000-10-18
ME00017B (me) 2010-06-10
BR0008840B1 (pt) 2011-12-27
DK1044977T3 (da) 2002-07-08
HU229506B1 (en) 2014-01-28
NO20014128D0 (no) 2001-08-24
EA200100954A1 (ru) 2002-04-25
ATE216998T1 (de) 2002-05-15
EG23999A (en) 2008-03-19
SK11642001A3 (sk) 2002-01-07
HRP20010667B1 (en) 2003-06-30
JP4610743B2 (ja) 2011-01-12
DE69901379D1 (de) 2002-06-06
PE20001485A1 (es) 2000-12-07
SK287561B6 (sk) 2011-02-04
US20010008939A1 (en) 2001-07-19
CA2362760A1 (en) 2000-09-14
EE04679B1 (et) 2006-08-15
SI1044977T1 (en) 2002-08-31
IL144958A (en) 2009-08-03
TWI272272B (en) 2007-02-01
EP1044977B1 (en) 2002-05-02
US6589939B2 (en) 2003-07-08
RS50405B (sr) 2009-12-31
TNSN00045A1 (fr) 2005-11-10
HK1031222A1 (en) 2001-06-08
HUP0200210A2 (hu) 2002-05-29
CN1343209A (zh) 2002-04-03
EA003605B1 (ru) 2003-06-26
PL355094A1 (en) 2004-03-22
AU774174B2 (en) 2004-06-17
WO2000053607A1 (en) 2000-09-14
HUP0200210A3 (en) 2004-03-29
BG65032B1 (bg) 2006-12-29

Similar Documents

Publication Publication Date Title
IS2003B (is) Kamptóþesín afleiður sem verka gegn æxlum
DE60009147T2 (de) Admantan derivate
IS5949A (is) Setnar bísýklískar afleiður gagnlegar sem miðlar gegn krabbameini
IS5818A (is) Alkýnýl-setnar kínólín-2-ón afleiður gagnlegar sem miðlar gegn krabbameini
IS2116B (is) 4-fenyl-pyridin afleiður
NO20021077L (no) Amino-triazolopyridin-derivater
EP1214333A4 (en) SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
ATE263748T1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
ATE273962T1 (de) 5-phenyl-pyrimidine derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
ATE293592T1 (de) Resorcinderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
DE69904738D1 (de) 2-phenylpyran-4-one derivate
NO20005031D0 (no) Kinolin-4-yl-derivater II
DE60015471D1 (de) Chinolin-4-yl-derivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DK1088818T3 (da) Quinolin-4-yl-derivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate